Abstract. In this case report a patient with thyroid dysfunction who received chronic treatment with interferon-alpha (INF-a) following a diagnosis of chronic myelogenous leukemia (CML) is described. Generally INF-a induced dysthyroidism develops in the earlier phase of INF-a treatment. This is a case report of thyroid dysfunction which occurred 4 years after the patient began to receive INF-a administration.
THE purpose of interferon-alpha (INF-a) treatment in patients with chronic myelogenous leukemia (CML) is to prolong life expectancy. On the other hand, this treatment results in many undesirable effects. The major side effects are fever, fatigue, depression, articular and muscle pain, loss of appetite, skin reactions and gastrointestinal symptoms. Serious and life threatening effects are fortunately rare. Sometimes INF-a therapy may provoke thyroid dysfunction in patients with or without preexisting thyroid dysfunction.
Clinical Report
A fifty-two-year old female patient with CML was hospitalized with recent onset of symptoms including dispnea on effort, palpitation, anxiety and weight loss on July 27, 1995.
Received: November 8, 1996 Accepted: June 20, 1997 Correspondence to: Dr. Ahmet OZET, Department of Medical Oncology, Gulhane Military Medical Academy, Ankara-TURKEY When the patient first applied to our hospital in 1991, she was diagnosed as having CML and was admitted to our clinic. The patient was treated with hydroxyurea and a 6 month course of INF-a (3 million units/m2/day three times weekly). The same therapy was continued 3 million units/m2/ day two times week with the addition of hydroxyurea.
Hydroxyurea therapy was applied according to the white blood cell count. The patient was in a chronic phase of CML under this treatment for the last 4 years.
Physical examination revealed a pulse rate of 114/min and grade 2/6 systolic heart murmur. An electrocardiogram showed sinus tachycardia. The white blood cell count was 12,000/mm3 and platelet count was 943,000/mm3. Peripheral blood smear confirmed the chronic phase of CML.
The thyroid function tests indicated hyperthyroidism.
Free T3 was 15.2 pg/ml (range 2.2-4.7), free T4 5.8 ng/dl (range 0.8-2.67) and thyroid stimulating hormone (TSH) < 0.13 micrIU/ ml (range < 6.5). The thyroid microsomal antibody level (< 50 IU/ml) and thyroglobuline antibody level (< 50 IU/ml) were found to be within the normal ranges (normal ranges: (negative -< 75) and, (negative -< 50), respectively). 
